The candidate vaccine raised neutralising antibodies in all dose cohorts after one immunisation , with seroconversion rates of 44 % ( n = 4 ) in the low-dose group , 92 % ( n = 11 ) in the medium-dose group , and 90 % ( n = 10 ) in the high-dose group .
